Reply to Alexander S. Parker, Brad C. Leibovich, Jeanette E. Eckel-Passow, John C. Cheville's letter to the editor re: Samira A. Brooks, A. Rose Brannon, Joel S. Parker, et al. ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma. Eur Urol 2014;66:77-84.

W Kimryn Rathmell, Samira A Brooks, Joel S Parker, Matthew E Nielsen

Abstract readLetterComment

In one paragraph

Article in European urology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

W Kimryn RathmellUNC Lineberger Cancer Center, Chapel Hill, NC, USA; Department of Medicine, Division of Hematology and Oncology, and Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: Rathmell@med.unc.edu.

Samira A BrooksUNC Lineberger Cancer Center, Chapel Hill, NC, USA.

Joel S ParkerUNC Lineberger Cancer Center, Chapel Hill, NC, USA.

Matthew E NielsenUNC Lineberger Cancer Center, Chapel Hill, NC, USA; Department of Urology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Funding

Enhancing Translational Science via Prospective InvestigationK24CA172355 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RATHMELL, WENDY KIMRYN · 2013 to 2017

$870k

NCI NIH HHS K24 CA172355

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Gene ExpressionAnimalsBiomarkers, TumorCarcinoma, Renal CellFemaleHumansKidney NeoplasmsMaleNeoplasm Recurrence, LocalBiomarkers, Tumor

Identifiers

PMID25037640

DOI10.1016/j.eururo.2014.07.002

PMCPMC4294998

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.